Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (191-200 of 252) with videos related to

Pageof 26
Sort By:
Intervirology|April 14, 2017
The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cARTAnne Emmanuelle Depincé, Elodie Dussert, Delphine Vergnon-Miszczycha, et al.
Digestive Diseases and Sciences|January 2, 2021
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's DiseaseFlorian Veyre, Gilles Boschetti, Camille Meunier, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2018
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative ColitisGauthier Pellet, Carmen Stefanescu, Franck Carbonnel, et al.
Journal of Crohn'S & Colitis|May 17, 2019
Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort AnalysisRobert D Little, Isabel E Chu, Esmerij P van der Zanden, et al.
Journal of Crohn'S & Colitis|March 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitisEmmanuel Niyigena, Yannick Hoffert, Waqqas Afif, et al.
Lancet (London, England)|December 19, 2016
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, Robert Petryka, et al.
Journal of Autoimmunity|April 7, 2017
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsisAnthony Lopez, Xavier Mariette, Hervé Bachelez, et al.
World Journal of Gastroenterology|March 23, 2022
Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional studyLaura Sirmai, Anne-Laure Pelletier, Nathalie Gault, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2024
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER StudyGuillaume Bouguen, Laure Gossec, Vered Abitbol, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Pageof 26

Showing results (191-200 of 252) with videos related to

Sort By:
Pageof 26
Intervirology|April 14, 2017
The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cARTAnne Emmanuelle Depincé, Elodie Dussert, Delphine Vergnon-Miszczycha, et al.
Digestive Diseases and Sciences|January 2, 2021
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's DiseaseFlorian Veyre, Gilles Boschetti, Camille Meunier, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2018
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative ColitisGauthier Pellet, Carmen Stefanescu, Franck Carbonnel, et al.
Journal of Crohn'S & Colitis|May 17, 2019
Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort AnalysisRobert D Little, Isabel E Chu, Esmerij P van der Zanden, et al.
Journal of Crohn'S & Colitis|March 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitisEmmanuel Niyigena, Yannick Hoffert, Waqqas Afif, et al.
Lancet (London, England)|December 19, 2016
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, Robert Petryka, et al.
Journal of Autoimmunity|April 7, 2017
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsisAnthony Lopez, Xavier Mariette, Hervé Bachelez, et al.
World Journal of Gastroenterology|March 23, 2022
Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional studyLaura Sirmai, Anne-Laure Pelletier, Nathalie Gault, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2024
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER StudyGuillaume Bouguen, Laure Gossec, Vered Abitbol, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Pageof 26